Antibiotic Resistance Market worth $18.34 Billion by 2030, page-3

With no knowledge of any commercialization negotiations in the pharma world, this 2 y waiting feels to be very long. ATH is most likely wanting to avoid the Nasdaq deadline in February and the Fund (if it is negotiating) perhaps would like to do the deal even this year as it told in April ( over 100M more investments this year). A traditional deal with Big Pharma could be easier, but not perhaps in this case because there are so many old antibiotics by many different companies that "need" PBT2 in combination with the old drug to kill previous resistant bacteria ( at least 30 old antibiotic drugs).
It will not take until 2030, but sitting at home and waiting week after week, makes everybody frustrated.